Clinical Research Study for Individuals with Postpartum Depression (PPD)
|Summary||PPD is a mood disorder that affects about 15% of women within the first year of childbirth. Women with PPD experience feelings of extreme sadness, hopelessness, suicidal ideation, anxiety, and fatigue. These symptoms mirror those of a major depressive episode with the additional criteria that the onset of depression occurs within 4 weeks of childbirth. PPD can affect a mother’s ability to care for her child and may negatively affect a child’s cognitive development.
The most common medications prescribed to women who seek treatment for PPD are SSRI’s and SNRI’s, which have limited evidence of efficacy. There are currently no approved therapies to treat PPD.
After childbirth, levels of hormones that are active in the mother’s central nervous system decline rapidly. It is thought that this rapid decline may play a role in triggering postpartum depression in some women. An investigative medication, ganaxolone, mimics the action of one of these hormones and may help alleviate the symptoms of depression. The purpose of the ongoing clinical trials is to test whether ganaxolone can be used to treat PPD.
The investigational medication has been dosed in more than 1,500 adults and children and has been reported to be generally safe and well tolerated. The study medication is a synthetic hormone that replicates the mood-boosting actions of some of the body’s natural pregnancy hormones.
There are several ongoing clinical trials across the US.
Call Us Now
|If you are 18 years of age or older and experiencing any of the following emotions or behaviors on most days of the week that may not have been present before becoming pregnant—-Call 877-788-3972
– Feeling depressed, hopeless or desperate
– Felt scared or panicky for no good reason
– Blamed yourself unnecessarily when things went wrong
– Felt anxious or worried for no good reason
Locations For This Trial